Tuesday, 21 Jan 2020

You are here

The RheumNow Week in Review – We’re Number One! (8.17.18)

Dr. Cush reviews the articles and news from the last week on RheumNow.com. Information on comorbidities, the downside of steroids, unmet need in psoriatic arthritis, and the top 10 rheumatology programs.

  1. Does Hep C cause RA? Claims data from Taiwan looked at HCV pts and found the risk of developing RA to be lower in those treated with interferon based therapy (HR 0.63 (95% CI 0.43 to 0.94, p=0.023). vs. untreated https://t.co/gEYlnPWMTb
  2. Australian Rheumatology Database comparison shows that psoriatic arthritis patients had greater odds of depression (OR 2.1), hypertension (1.7), hyperlipidemia (2.0), diabetes (2.2) & ischemic heart disease (2.0). https://t.co/ZUwUAJmUIV
  3. RA patients who develop lung cancer are more likely to be diagnosed at an advanced stage and have a poorer performance scores & are less likely to receive surgery, radiotherapy, chemotherapy or targeted therapy. https://t.co/Fre8pQQ0bL
  4. Study of UK Clinical Practice Research Database shows that in #RA, steroid use assoc w/ increased risk of diabetes (OR 1.33), OP (1.41) thrombotic stroke or MI (1.28), serious infection (1.28), & death (1.33), with many of these being dose related https://t.co/RDxwpLByFA
  5. Managing Comorbidity and Poor Drug Responses
  6. There is no association between rising MCV levels and hematologic toxicity of methotrexate https://t.co/CcNfyKrTb2
  7. Data from a prospective longitudinal cohort of PsA patients shows that greater Xray damage is associated with exposure to prolonged repetitive hand movements and occupations with higher level of finger dexterity https://t.co/4yrAIPFKnK
  8. Unmet need in Psoriatic Arthritis! 10 Yr study of 331 PsA pts from Norway shows no increase in remission rates, no signif change in PRO's and no increase in DMARD or biologic use. Large need for T2T remission in PsA. https://t.co/dbZGyavXfY
  9. Early Exposure to Passive Smoke May Up Risk for RA Later in Life   
  10. Tumor Necrosis Factor Inhibitors Do Not Increase the Risk of Cancer Recurrence  
  11. U.S. News 2018-19 Rheumatology Rankings 
  12. Drugs causing a metallic taste? Antibiotics (including tetracycline and amoxicillin), lithium (used to treat psychiatric disorders), certain cardiac medications, and allopurinol (which treats gout and kidney stones)  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

CDC: 15% of US Adults are Physically Inactivie

All states and territories had more than 15% of adults who were physically inactive and this estimate ranged from 17.3 to 47.7%,  according to new state maps of adult physical inactivity prevalence released today by the Centers for Disease Control and Prevention (CDC).

RheumNow Podcast- The Down Side of Steroids (1.17.20)

Dr. Jack Cush reviews the journal reports and news from RheumNow.com. Be sure to register for RheumNow Live 3/13/2020 in Fort Worth Rheumnow.live.

RheumNow Podcast- Knee Pain Knockout (1.10.20)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. The podcast covers: best therapies for dactylitis and enthesitis; we have a new knockout for knee pain in OA; and are you on the naughty or nice list when it comes to the new ACR-AF guidelines for arthritis? This and more. Tune in.

2019 Rheumatology Year in Review

2019 was a year marked by major advances, hallmark research, and big news items affecting rheumatology.   Herein you will find our top 10 list, formulated by what I think rheumatologists should know and what will likely change their standards and practice in 2020 and beyond. 

RheumNow Podcast - 2019 Rheumatology Year in Review

Dr. Jack Cush reviews highlights from 2019 on RheumNow.com. Topics covered in this annual review include: superheroes lost; venous thromboembolic events and JAKs; free medical tuition; women in rheumatology; 52 new drug approvals in 2019 and 330 drugs with a 2020 price hike; scleroderma disappointments; novel new treatments and newer tests; the boom of Shingrix; RheumNow.Live - and more.